A press release has been issued by Satsuma Pharmaceuticals, Inc.
- Business
Announcement Date: December 20, 2022 (U.S. Time)
Details: Our key investment company, Satsuma, Intranasal Migraine Medication (Development Code: STS101) We have issued a press release regarding the development status. For more details, Here Please refer to the original text from here.